Keyword: Advaxis

Regulatory officials took the action upon learning a cervical cancer patient developed respiratory failure and died after receiving the combination.

AZ CEO Pascal Soriot was said to be joining Teva as CEO, GSK poached Pfizer's medicinal sciences head, and Advaxis CEO O'Connor abruptly resigned.

Daniel O’Connor has resigned as CEO of Advaxis, which has put CBO Tony Lombardo in charge while it searches for a permanent successor.

Juno tapped Genentech alum Sunil Agarwal as new R&D chief, Merrimack promoted Onivyde scientist Daryl Drummond as head of research, and Mitch Gold leads the newly merged Alpine.

Advaxis and Amgen get an FDA OK to start testing their neoantigen cancer vaccine, partnered in a $540 million deal last year.

Advaxis has licensed its antigen delivery technology for use in Sellas’ cancer immunotherapy.

Though the FDA hit its studies with a clinical hold last year, which it lifted after two months, small cap Advaxis has posted some updated topline data to back up previous reports that its new med can help some patients make significant gains in overall survival rates.

After a rough year in which trials of its lead treatment were put on an FDA hold, small cap biotech Advaxis is bouncing back with a recent deal with Amgen and today, some good news coming out of its pipeline about that once-halted med.

Small cap Advaxis has a new preclinical immuno-oncology deal with industry giant Amgen that gives it $65 million in an upfront payment and investment.